These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 36378541)
1. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541 [TBL] [Abstract][Full Text] [Related]
2. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745 [TBL] [Abstract][Full Text] [Related]
4. Molecular features and evolutionary trajectory of ASCL1 Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551 [TBL] [Abstract][Full Text] [Related]
5. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma. Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667 [TBL] [Abstract][Full Text] [Related]
6. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040 [TBL] [Abstract][Full Text] [Related]
7. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388 [TBL] [Abstract][Full Text] [Related]
8. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118 [TBL] [Abstract][Full Text] [Related]
9. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression. Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517 [TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573 [TBL] [Abstract][Full Text] [Related]
12. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. Peressini M; Garcia-Campelo R; Massuti B; Martí C; Cobo M; Gutiérrez V; Dómine M; Fuentes J; Majem M; de Castro J; Córdoba JF; Diz MP; Isla D; Esteban E; Carcereny E; Vila L; Moreno-Vega A; Ros S; Moreno A; García FJ; Huidobro G; Aguado C; Cebey-López V; Valdivia J; Palmero R; Lianes P; López-Brea M; Vidal OJ; Provencio M; Arriola E; Baena J; Herrera M; Bote H; Molero M; Adradas V; Ponce-Aix S; Nuñez-Buiza A; Ucero Á; Hernandez S; Lopez-Rios F; Conde E; Paz-Ares L; Zugazagoitia J Clin Cancer Res; 2024 Jul; 30(14):3036-3049. PubMed ID: 38630755 [TBL] [Abstract][Full Text] [Related]
13. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245 [TBL] [Abstract][Full Text] [Related]
14. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor. Kim G; Kim M; Nam EJ; Lee JY; Park E Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832 [TBL] [Abstract][Full Text] [Related]
15. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466 [TBL] [Abstract][Full Text] [Related]
16. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells. Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975 [TBL] [Abstract][Full Text] [Related]
18. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888 [TBL] [Abstract][Full Text] [Related]
19. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603 [TBL] [Abstract][Full Text] [Related]
20. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer. Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]